Harvard Bioscience Inc. (HBIO)
Harvard Bioscience Statistics
Share Statistics
Harvard Bioscience has 44.07M shares outstanding. The number of shares has increased by 0.5% in one year.
| Shares Outstanding | 44.07M |
| Shares Change (YoY) | 0.5% |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | 70.68% |
| Shares Floating | 38.04M |
| Failed to Deliver (FTD) Shares | 602 |
| FTD / Avg. Volume | 0.19% |
Short Selling Information
The latest short interest is 785.13K, so 1.8% of the outstanding shares have been sold short.
| Short Interest | 785.13K |
| Short % of Shares Out | 1.8% |
| Short % of Float | 1.95% |
| Short Ratio (days to cover) | 3.12 |
Valuation Ratios
The PE ratio is -7.41 and the forward PE ratio is 13.68. Harvard Bioscience's PEG ratio is -0.03.
| PE Ratio | -7.41 |
| Forward PE | 13.68 |
| PS Ratio | 0.98 |
| Forward PS | 0.3 |
| PB Ratio | 1.45 |
| P/FCF Ratio | -76.3 |
| PEG Ratio | -0.03 |
Enterprise Valuation
Harvard Bioscience Inc. has an Enterprise Value (EV) of 265.44M.
| EV / Earnings | -21.4 |
| EV / Sales | 2.82 |
| EV / EBITDA | -204.34 |
| EV / EBIT | -42.74 |
| EV / FCF | -220.46 |
Financial Position
The company has a current ratio of 0.82, with a Debt / Equity ratio of 0.7.
| Current Ratio | 0.82 |
| Quick Ratio | 0.4 |
| Debt / Equity | 0.7 |
| Total Debt / Capitalization | 41.26 |
| Cash Flow / Debt | 0.03 |
| Interest Coverage | -1.94 |
Financial Efficiency
Return on equity (ROE) is -0.2% and return on capital (ROIC) is -6.13%.
| Return on Equity (ROE) | -0.2% |
| Return on Assets (ROA) | -0.1% |
| Return on Capital (ROIC) | -6.13% |
| Revenue Per Employee | $285,257.58 |
| Profits Per Employee | $-37,590.91 |
| Employee Count | 330 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 1.69 |
Taxes
| Income Tax | 740K |
| Effective Tax Rate | -0.06 |
Stock Price Statistics
The stock price has increased by -85.48% in the last 52 weeks. The beta is 1.47, so Harvard Bioscience's price volatility has been higher than the market average.
| Beta | 1.47 |
| 52-Week Price Change | -85.48% |
| 50-Day Moving Average | 1.21 |
| 200-Day Moving Average | 2.27 |
| Relative Strength Index (RSI) | 22.58 |
| Average Volume (20 Days) | 312.71K |
Income Statement
In the last 12 months, Harvard Bioscience had revenue of 94.14M and earned -12.4M in profits. Earnings per share was -0.28.
| Revenue | 94.14M |
| Gross Profit | 54.77M |
| Operating Income | -6.21M |
| Net Income | -12.4M |
| EBITDA | -1.3M |
| EBIT | -6.21M |
| Earnings Per Share (EPS) | -0.28 |
Balance Sheet
The company has 4.11M in cash and 44.49M in debt, giving a net cash position of -40.39M.
| Cash & Cash Equivalents | 4.11M |
| Total Debt | 44.49M |
| Net Cash | -40.39M |
| Retained Earnings | -158.01M |
| Total Assets | 126.64M |
| Working Capital | -9.84M |
Cash Flow
In the last 12 months, operating cash flow was 1.44M and capital expenditures -2.64M, giving a free cash flow of -1.2M.
| Operating Cash Flow | 1.44M |
| Capital Expenditures | -2.64M |
| Free Cash Flow | -1.2M |
| FCF Per Share | -0.03 |
Margins
Gross margin is 58.18%, with operating and profit margins of -6.6% and -13.18%.
| Gross Margin | 58.18% |
| Operating Margin | -6.6% |
| Pretax Margin | -12.39% |
| Profit Margin | -13.18% |
| EBITDA Margin | -1.38% |
| EBIT Margin | -6.6% |
| FCF Margin | -1.28% |
Dividends & Yields
HBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -45.9% |
| FCF Yield | -4.46% |
Analyst Forecast
The average price target for HBIO is $4.5, which is 637.7% higher than the current price. The consensus rating is "Hold".
| Price Target | $4.5 |
| Price Target Difference | 637.7% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Nov 4, 2013. It was a forward split with a ratio of 1319:1000.
| Last Split Date | Nov 4, 2013 |
| Split Type | forward |
| Split Ratio | 1319:1000 |
Scores
| Altman Z-Score | -1.09 |
| Piotroski F-Score | 4 |